Quince Therapeutics, Inc. (QNCX)
Automate Your Wheel Strategy on QNCX
With Tiblio's Option Bot, you can configure your own wheel strategy including QNCX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QNCX
- Rev/Share 0.0
- Book/Share 0.0196
- PB 9.1702
- Debt/Equity 16.9906
- CurrentRatio 1.1213
- ROIC -0.4555
- MktCap 10022668.0
- FreeCF/Share -0.7224
- PFCF -0.2571
- PE -0.1704
- Debt/Assets 0.1637
- DivYield 0
- ROE -3.7046
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | QNCX | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | Jan. 30, 2026 |
| Initiation | QNCX | Citizens JMP | -- | Mkt Outperform | -- | $9 | Aug. 5, 2025 |
| Initiation | QNCX | Oppenheimer | -- | Outperform | -- | $10 | March 24, 2025 |
News
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Published: January 29, 2026 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T). In the NEAT study, the company's pivotal Phase 3 in.
Read More
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Negative
Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment.
Read More
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with high price targets, and robust patent protection highlight growing confidence and upside potential. Data readout for the NEAT Phase 3 trial is scheduled for early 2026, with all patients joining the open-label extension, and cash runway aligns with expected topline results.
Read More
About Quince Therapeutics, Inc. (QNCX)
- IPO Date 2019-05-09
- Website https://www.quincetx.com
- Industry Biotechnology
- CEO Dirk Thye
- Employees 36